Should You Buy Day One Biopharmaceuticals Inc (DAWN) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
BUY (starter position now). Despite today’s -4.46% regular-session drop to $11.78, DAWN’s medium-term technical structure is still bullish (SMA_5 > SMA_20 > SMA_200) and options positioning is strongly call-leaning, while Wall Street price targets (mid-$20s) imply substantial upside from the current level. For a beginner with a long-term preference and $50k–$100k available, this is a reasonable “buy now” entry rather than waiting for a perfect pullback—size it as an initial tranche given the weak latest-quarter growth profile and the binary nature of biotech execution.
Technical Analysis
Trend/structure: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests the broader trend remains constructive even after the sharp daily selloff. Momentum: MACD histogram is positive (0.134) but contracting, indicating upside momentum is slowing (not reversing yet). RSI(6)=56.5 is neutral—no overbought condition and not deeply oversold. Key levels: Pivot support near 11.547 is immediately in play; a clean hold above this area supports buying on weakness. Near-term resistance is R1 ~12.83, then R2 ~13.623. If price loses the pivot area, next supports are ~10.263 (S1) and ~9.47 (S2). Pattern-based odds: similar-pattern model suggests a slightly negative next day (-1.63% bias) but positive next week/month (+5.17% / +6.8%), aligning with a buy-for-weeks-to-months view rather than a one-day trade.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Analyst Ratings and Price Target Trends
Recent trend: Both cited notes are positive and include price-target increases. On 2025-11-07, JPMorgan raised PT to $27 (from $26) and reiterated Overweight. On 2025-11-05, Piper Sandler raised PT to $26 (from $25) and reiterated Overweight, explicitly calling valuation an attractive entry ahead of ongoing commercial execution and longer-term data (including 1L pLGG data referenced for 2027). Wall Street pros: clear bullish stance and materially higher targets than the current ~$11.78 price. Cons: the bullish view is contingent on execution/data timing; the latest quarter’s YoY contraction makes the story less “fundamentals-supported” right now.
Influential/political trading check: No recent congress trading data available; hedge fund and insider trends are listed as Neutral (no significant recent buying/selling signals).
Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 24.13 USD with a low forecast of 16 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 24.13 USD with a low forecast of 16 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 12.330
Current: 12.330
